Sharma et al. (2011) conducted a 12-week open-label study in patients who were on hemodialysis and were taking MV-ONE PLUS. At the end of the study, vitamin D (25-OH) levels increased significantly by 33% (P=0.0058); a slight increase in the intravenous vitamin D dose was also observed, but it was not statistically significant. This increase could be explained by an interstudy facility change in vitamin D therapies during the study period.

Further, a decrease in ESA dose was reported (P=0.0475), while hemoglobin, transferrin saturation, and platelet values remained stable. The study also reported the cost-effective benefits of using MV-ONE PLUS. Although the findings suggest that MV-ONE PLUS could be a useful and cost-effective, additional studies are needed to validate these findings.

Currently, a larger evaluation in the clinical setting is in progress, with preliminary data expected shortly. MV-ONE PLUS appears to be well tolerated in patients who have participated in the study for 12 months or longer.